An interventional study of Remimazolam (Byfavo) and Propofol in Hip Fractures, Knee Osteoarthritis and Femur Fracture, sponsored by Inje University. Recruiting at 1 site in South Korea. Open to participants aged 65 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Inje University · Not applicable, Interventional, and Other
Remimazolam is an ultra-short acting benzodiazepine agonist which is used widely for general anesthesia and sedation. Remimazolam has several advantages. Remimazolam is rapidly metabolized by tissue esterase that it does not accumulate even after infusion for long periods of time. The presence of reversal agents (flumazenil) is also advantageous. Also, hemodynamic stability compared to propofol gives clinicians preference to use for geriatric anesthesia. However, the study on the effect of remimazolam compared to propofol on postoperative delirium have not been carried out. The purpose of the study is to compare the incidence of postoperative delirium and recovery profile in elderly patients undergoing orthopedic surgery using either remimazolam or propofol.
842 studies on the registry are indexed under Hip Fractures; 165 are open to participants now.
This study's planned enrollment of 82 is close to the median of 86 across 533 interventional studies indexed under Hip Fractures.
Browse Hip Fractures studies →Inje University is the lead sponsor of 93 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Remimazolam is started during induction of anesthesia at the rate of 6 mg/kg/hr and continued at the rate of 1 mg/kg/hr (within 0.3-2 mg/kg/hr). Remimazolam is stopped 20 minutes before end of operation.
Drug: Remimazolam (Byfavo)
Propofol is continuously infused within 1-5 μg/mL.
Drug: Propofol
Remimazolam is continuously infused based on bispectral index (within 40-60).
Propofol is continuously infused based on bispectral index (within 40-60).
Incidence of delirium 3 days after the end of operation
delirium is evaluated preoperatively and 3 days after surgery using Mini-Mental State Examination
Time frame: Upto 3 days after surgery
quality of recovery (QoR-15) 3 days after the end of the operation
QoR-15 survey is performed preoperatively and 3 days after surgery.
Time frame: Upto 3 days after surgery
Started Aug 2022 (actual). Primary completion is estimated for Aug 2026, 48 months after the start.
Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 48 months is above that.
Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remimazolam besilate
Inje University